Story
AbbVie's Rinvoq Secures EU Approval for Pediatric Arthritis
AbbVie Inc. (NYSE: ABBV) announced on Tuesday that it has received approval from the European Commission for its drug Rinvoq to treat a form of pediatric arthritis, further expanding the blockbuster drug's list of approved uses in the European Union.
Details of the Approval
According to a statement from the pharmaceutical company, the approval covers the use of Rinvoq, known generically as upadacitinib, for the treatment of active polyarticular juvenile idiopathic arthritis.
The therapy is now authorized for patients two years of age and older who have not responded adequately to one or more prior disease-modifying anti-rheumatic drugs (DMARDs).
Strategic Importance for AbbVie
AdThis latest regulatory milestone is significant for AbbVie as it broadens the addressable market for Rinvoq, a key asset in the company's immunology portfolio and a critical component of its growth strategy.
Expanding the label for key drugs is crucial for AbbVie as it seeks to build revenue streams beyond its older blockbuster, Humira. Rinvoq is already a major commercial success, with existing EU approvals for several other inflammatory conditions, including:
- Rheumatoid arthritis
- Psoriatic arthritis
- Atopic dermatitis
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.